Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia

Blood

Volumn 122, Issue 12, 2013, Pages 2074-2082

  Ma, Ji ^a   Ning, Yun Na ^b   Xu, Miao ^a   Hou, Yu ^c   Wang, Ning ^a   Hou, Xiao Yan ^a   Yu, Ying Yi ^c   Li, Hui ^a   He, Wei Dong ^d   Shao, Lin Lin ^a   Zhou, Hai ^a   Min, Ya Nan ^a   Liu, Xin Guang ^a   Shi, Yan ^a   Qin, Ping ^a   Guo, Cheng Shan ^a   Hou, Ming ^a,e   Peng, Jun ^a,e  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d Blood Center of Shandong Province   (China)

^e BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; CASPASE 8; GLUCOCORTICOID; IMMUNOGLOBULIN G; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; ORGANIC CATION TRANSPORTER 3; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA1; EARLY GROWTH RESPONSE FACTOR; IMMUNOSUPPRESSIVE AGENT; KLF10 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; MALE; MESENCHYMAL STEM CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UPREGULATION; CASE CONTROL STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; RNA INTERFERENCE;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CELL PROLIFERATION; DENDRITIC CELLS; EARLY GROWTH RESPONSE TRANSCRIPTION FACTORS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RNA INTERFERENCE; THALIDOMIDE; YOUNG ADULT;

EID: 84887571005     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-491555     Document Type: Article

References (50)

1. De Sanctis JB, Mijares M, Suárez A, et al. Pharmacological properties of thalidomide and its analogues. Recent Pat Inflamm Allergy Drug Discov. 2010;4(2):144-148.
2. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 1993;168(2):408-414.
3. Lenardo TM, Calabrese LH. The role of thalidomide in the treatment of rheumatic disease. J Clin Rheumatol. 2000;6(1):19-26.
4. Bariol C, Meagher AP, Vickers CR, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol. 2002;17(2):135-139.
5. Falco P, Bertola A, Bringhen S, Cavallo F, Boccadoro M, Palumbo A. Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma. Hematol J. 2004;5(5):456-457.
6. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4): 574-596.
7. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11): 2386-2393.
8. Semple JW, Freedman J. Cellular immune mechanisms in chronic autoimmune thrombocytopenic purpura (ATP). Autoimmunity. 1992;13(4):311-319.
9. Semple JW, Provan D, Garvey MB, Freedman J. Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol. 2010;17(6):590-595.
10. Pérez-Simón JA, Tabera S, Sarasquete ME, et al. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy. 2009; 11(6):698-705.
11. Wang H, Pang B, Li Y, Zhu D, Pang T, Liu Y. Dexamethasone has variable effects on mesenchymal stromal cells. Cytotherapy. 2012; 14(4):423-430.
12. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284(5411):143-147.
13. Jorgensen C, Djouad F, Apparailly F, Nöel D. Engineering mesenchymal stem cells for immunotherapy. Gene Ther. 2003;10(10): 928-931.
14. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 2005;105(7):2821-2827.
15. Tabera S, Pérez-Simón JA, Díez-Campelo M, et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica. 2008;93(9): 1301-1309.
16. Zhang W, Ge W, Li C, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocytederived dendritic cells. Stem Cells Dev. 2004; 13(3):263-271.
17. Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005;105(10):4120-4126.
18. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD341-derived and monocyte-derived dendritic cells. J Immunol. 2006;177(4):2080-2087.
19. Zhang B, Liu R, Shi D, et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood. 2009;113(1):46-57.
20. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003; 101(9):3722-3729.
21. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol. 2003;171(7):3426-3434.
22. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigenpresenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105(5): 2214-2219.
23. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity. 2003;18(5): 605-617.
24. Sanz MA, Vicente Garcia V, Fernandez A, et al. Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia [in Spanish]. Med Clin (Barc). 2012;138(6):261. e261-261.e217.
25. Pérez-Ilzarbe M, Díez-Campelo M, Aranda P, et al. Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy. Transfusion. 2009;49(9):1901-1910.
26. Wobus M, Benath G, Ferrer RA, et al. Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. Exp Hematol. 2012;40(10):867-876.
27. Zhang XL, Peng J, Sun JZ, et al. De novo induction of platelet-specific CD4(1)CD25(1) regulatory T cells from CD4(1)CD25(-) cells in patients with idiopathic thrombocytopenic purpura. Blood. 2009;113(11):2568-2577.
28. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSCderived prostaglandin E2. Blood. 2009;113(26): 6576-6583.
29. Kodama T, Abe M, Iida S, et al. A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma. Clin Lymphoma Myeloma. 2009;9(2): 154-159.
30. Seo KW, Lee SR, Bhandari DR, et al. OCT4A contributes to the stemness and multi-potency of human umbilical cord blood-derived multipotent stem cells (hUCB-MSCs). Biochem Biophys Res Commun. 2009;384(1):120-125.
31. Pello OM, De Pizzol M, Mirolo M, et al. Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood. 2012;119(2):411-421.
32. Saulnier N, Puglisi MA, Lattanzi W, et al. Gene profiling of bone marrow- and adipose tissuederived stromal cells: a key role of Kruppel-like factor 4 in cell fate regulation. Cytotherapy. 2011; 13(3):329-340.
33. Audia S, Samson M, Guy J, et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood. 2011;118(16): 4394-4400.
34. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol. 2000;37(3):239-248.
35. Olsson B, Andersson PO, Jern°as M, et al. T-cellmediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123-1124.
36. Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008; 112(4):1325-1328.
37. Liu B, Zhao H, Poon MC, et al. Abnormality of CD4(1)CD25(1) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 2007; 78(2):139-143.
38. Li X, Zhong H, Bao W, et al. Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood. 2012;120(16): 3318-3325.
39. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10): 3838-3843.
40. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75(3):389-397.
41. Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103(12):4619-4621.
42. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815-1822.
43. Fang B, Mai L, Li N, Song Y. Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cells. Stem Cells Dev. 2012;21(3):497-502.
44. Xiao J, Zhang C, Zhang Y, et al. Transplantation of adipose-derived mesenchymal stem cells into a murine model of passive chronic immune thrombocytopenia. Transfusion. 2012;52(12): 2551-2558.
45. Sato K, Yamashita N, Yamashita N, Baba M, Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity. 2003;18(3): 367-379.
46. Sato K, Yamashita N, Baba M, Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood. 2003;101(9):3581-3589.
47. Smits HH, de Jong EC, Wierenga EA, Kapsenberg ML. Different faces of regulatory DCs in homeostasis and immunity. Trends Immunol. 2005;26(3):123-129.
48. Sato K, Yamashita N, Matsuyama T. Human peripheral blood monocyte-derived interleukin- 10-induced semi-mature dendritic cells induce anergic CD4(1) and CD8(1) T cells via presentation of the internalized soluble antigen and cross-presentation of the phagocytosed necrotic cellular fragments. Cell Immunol. 2002; 215(2):186-194.
49. Subramaniam M, Harris SA, Oursler MJ, Rasmussen K, Riggs BL, Spelsberg TC. Identification of a novel TGF-beta-regulated gene encoding a putative zinc finger protein in human osteoblasts. Nucleic Acids Res. 1995;23(23): 4907-4912.
50. Johnsen SA, Subramaniam M, Janknecht R, Spelsberg TC. TGFbeta inducible early gene enhances TGFbeta/Smad-dependent transcriptional responses. Oncogene. 2002; 21(37):5783-5790.